


## Gemcitabine

<b>Cat. No.:</b>	HY-17026
<b>CAS No.:</b>	95058-81-4
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>11</sub> F <sub>2</sub> N <sub>3</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	263.2
<b>Target:</b>	Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Autophagy; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Autophagy; Apoptosis
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 250 mg/mL (949.85 mM; Need ultrasonic)  
Ethanol : 12.5 mg/mL (47.49 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.7994 mL	18.9970 mL	37.9939 mL
	5 mM	0.7599 mL	3.7994 mL	7.5988 mL
	10 mM	0.3799 mL	1.8997 mL	3.7994 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 0.5%HPMC >> 1%Tween80  
Solubility: 20 mg/mL (75.99 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline  
Solubility: ≥ 2.62 mg/mL (9.95 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.62 mg/mL (9.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution

## BIOLOGICAL ACTIVITY

<b>Description</b>	Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagy and apoptosis <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	DNA synthesis <sup>[1]</sup>								
<b>In Vitro</b>	<p>Gemcitabine (purchased from MedChem Express, 0.003-1 <math>\mu</math>M; 3 days) kills both mouse and human senescent cells effectively and potently<sup>[4]</sup>.</p> <p>Gemcitabine inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC<sub>50</sub>s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[4]</sup></p> <table><tr><td>Cell Line:</td><td>Non-senescent and replication-induced senescent new born dermal fibroblasts (NBFs)</td></tr><tr><td>Concentration:</td><td>0.003, 0.01, 0.03, 0.1, 0.3, 1 <math>\mu</math>M</td></tr><tr><td>Incubation Time:</td><td>3 days</td></tr><tr><td>Result:</td><td>Killed replication-induced senescent NBFs for 3 days with 11.0% cell viability.</td></tr></table>	Cell Line:	Non-senescent and replication-induced senescent new born dermal fibroblasts (NBFs)	Concentration:	0.003, 0.01, 0.03, 0.1, 0.3, 1 $\mu$ M	Incubation Time:	3 days	Result:	Killed replication-induced senescent NBFs for 3 days with 11.0% cell viability.
Cell Line:	Non-senescent and replication-induced senescent new born dermal fibroblasts (NBFs)								
Concentration:	0.003, 0.01, 0.03, 0.1, 0.3, 1 $\mu$ M								
Incubation Time:	3 days								
Result:	Killed replication-induced senescent NBFs for 3 days with 11.0% cell viability.								
<b>In Vivo</b>	<p>Gemcitabine can be administered via endotracheal spray in rats without marked toxicity with a maximum tolerated dose of 4 mg/kg once a week for 9 weeks. The toxicity of Gemcitabine is lower via lung than oral administration at dosages of 2, 4, and 6 mg/kg<sup>[2]</sup>.</p> <p>Treatment of the LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H</sup>; Pdx-1-Cre mice with either Gemcitabine (50 mg/kg, i.p.) or the combination DMAPT/Gemcitabine significantly increases the median survival time by more than 30 days compared to the placebo group (254.5 or 255 days vs. 217.5 days, respectively)<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

## CUSTOMER VALIDATION

- Nature. 2019 Oct;574(7777):264-267.
- Adv Mater. 2021 May;33(18):e2100949.
- Cell Res. 2020 Jul;30(7):574-589.
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23.
- Sci Transl Med. 2021 Jan 20;13(577):eaba7401.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1. *Anticancer Res.* 2011 Oct;31(10):3171-80.
- [2]. Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. *BMC Cancer.* 2013 Apr 17;13:194.
- [3]. Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. *J Aerosol Med.* 2005 Summer;18(2):198-206

---

[4]. Yusheng Cai, et al. Elimination of senescent cells by  $\beta$ -galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA